Advisory Services Network’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Hold
0
-$2 2871
2023
Q4
Hold
0
3863
2023
Q2
Hold
0
-$2 2846
2023
Q1
Hold
0
3986
2022
Q4
Hold
0
3988
2020
Q4
Sell
-7
Closed -$2K 3558
2020
Q3
$2K Buy
+7
New +$2.2K ﹤0.01% 3144
2020
Q2
Sell
-243
Closed -$65K 2135
2020
Q1
$65K Buy
243
+100
+70% +$30.9K ﹤0.01% 1255
2019
Q4
$47K Buy
143
+133
+1,330% +$38.6K ﹤0.01% 1517
2019
Q3
$5K Hold
10
﹤0.01% 2416
2019
Q2
$5K Sell
10
-13
-57% -$6.52K ﹤0.01% 2414
2019
Q1
$12K Buy
23
+6
+35% +$3.56K ﹤0.01% 1796
2018
Q4
$8K Sell
17
-43
-72% -$26K ﹤0.01% 1845
2018
Q3
$54K Hold
60
﹤0.01% 1197
2018
Q2
$45K Buy
60
+57
+1,900% +$65.7K ﹤0.01% 1252
2018
Q1
$5K Sell
3
-4
-57% -$5.15K ﹤0.01% 2123
2017
Q4
$6K Buy
+7
New +$4.14K ﹤0.01% 2043
2016
Q3
$7K Hold
27
﹤0.01% 1420
2016
Q2
$6K Buy
+27
New +$6.04K ﹤0.01% 1360
2015
Q4
Sell
-13
Closed -$2K 1587
2015
Q3
$2K Hold
13
﹤0.01% 1342
2015
Q2
$2K Hold
13
﹤0.01% 1278
2015
Q1
$2K Buy
+13
New +$2.67K ﹤0.01% 1189

Other funds holding NKTR

Advisory Services Network's NKTR Position: Q1 2024 in Review

Advisory Services Network held its Nektar Therapeutics (NKTR) position steady in Q1 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2871.

Advisory Services Network first reported a position in NKTR in Q1 2015 and has held it in 16 quarters since. The position peaked at $65K in Q1 2020. 124 funds tracked by Wall St. Rank hold NKTR as of Q1 2024.

  • Advisory Services Network held 0 shares of Nektar Therapeutics worth $0 as of Q1 2024.
  • Advisory Services Network left its Nektar Therapeutics share count unchanged in Q1 2024.
  • Nektar Therapeutics made up ﹤0.01% of Advisory Services Network's portfolio in Q1 2024, its #2871 holding.
  • Advisory Services Network first reported a position in Nektar Therapeutics in Q1 2015 and has held it in 16 quarters since.
  • Advisory Services Network's Nektar Therapeutics position peaked at $65K in Q1 2020.
  • 124 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2024.

Based on Advisory Services Network's 13F filing for Q1 2024, filed 6 May 2024.